Miglustat
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00419 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | autosomal ichthyosis syndrome with fatal disease course | KG + DL |
| 2 | cholesteryl ester storage disease | KG + DL |
| 3 | Krabbe disease | KG + DL |
| 4 | metachromatic leukodystrophy | KG + DL |
| 5 | Wolman disease with hypolipoproteinemia and acanthocytosis | KG + DL |
| 6 | encephalopathy due to prosaposin deficiency | KG + DL |
| 7 | Tay-Sachs disease | KG + DL |
| 8 | benign neoplasm of adrenal gland | KG + DL |
| 9 | recessive X-linked ichthyosis | KG + DL |
| 10 | fatty acid hydroxylase-associated neurodegeneration | KG + DL |
| 11 | lysosomal acid lipase deficiency | KG + DL |
| 12 | cholesterol metabolism disease | KG + DL |
| 13 | adult Krabbe disease | KG + DL |
| 14 | polycystic kidney disease 3 with or without polycystic liver disease | KG + DL |
| 15 | long chain 3-hydroxyacyl-CoA dehydrogenase deficiency | KG + DL |
| 16 | multiple mitochondrial dysfunctions syndrome | KG + DL |
| 17 | cerebrotendinous xanthomatosis | KG + DL |
| 18 | Dorfman-Chanarin disease | KG + DL |
| 19 | fatty acyl-CoA reductase 1 deficiency | KG + DL |
| 20 | gangliosidosis | KG + DL |
| 21 | congenital ichthyosis-intellectual disability-spastic quadriplegia syndrome | KG + DL |
| 22 | Wolman disease | KG + DL |
| 23 | free sialic acid storage disease | KG + DL |
| 24 | lipoprotein glomerulopathy | KG + DL |
| 25 | Joubert syndrome with renal defect | KG + DL |
| 26 | infantile cerebellar-retinal degeneration | KG + DL |
| 27 | fumaric aciduria | KG + DL |
| 28 | renal-hepatic-pancreatic dysplasia | KG + DL |
| 29 | hyperphenylalaninemia due to DNAJC12 deficiency | KG + DL |
| 30 | congenital cataract-hearing loss-severe developmental delay syndrome | KG + DL |
| 31 | karyomegalic interstitial nephritis | KG + DL |
| 32 | mucosulfatidosis | KG + DL |
| 33 | dopa-responsive dystonia | KG + DL |
| 34 | Cushing disease due to pituitary adenoma | KG + DL |
| 35 | Sandhoff disease | KG + DL |
| 36 | Hurler syndrome | KG + DL |
| 37 | GM1 gangliosidosis | KG + DL |
| 38 | pyridoxine-dependent epilepsy | KG + DL |
| 39 | coenzyme Q10 deficiency | KG + DL |
| 40 | hereditary spastic paraplegia | KG + DL |
| 41 | oxoglutaricaciduria | KG + DL |
| 42 | aminoacylase 1 deficiency | KG + DL |
| 43 | neuronal ceroid lipofuscinosis 8 northern epilepsy variant | KG + DL |
| 44 | thoracic malformation | KG + DL |
| 45 | mitochondrial pyruvate carrier deficiency | KG + DL |
| 46 | adult familial nephronophthisis-spastic quadriparesia syndrome | KG + DL |
| 47 | biotin-responsive basal ganglia disease | KG + DL |
| 48 | AGAT deficiency | KG + DL |
| 49 | GM2 gangliosidosis | KG + DL |
| 50 | squalene synthase deficiency | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.